RUNX2 and neoplasm: Indeed, pharmacological delivery of synthetic miR-135 and miR-203 mimics into metastatic breast cancer cells reduces Runx2 protein abundance and consequently, diminishes tumor growth and spontaneous metastasis to bone (72).